Tafe Laura J
One Medical Center Drive, Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03754, USA.
Virchows Arch. 2017 Aug;471(2):155-164. doi: 10.1007/s00428-017-2101-7. Epub 2017 Mar 10.
The goal of personalized cancer therapy is to treat tumors based on genomic aberrations that drive their survival and progression. Most patients who receive targeted therapies typically develop resistance and disease progression within a year's time. This review focuses on the heterogeneous mechanisms of therapy resistance to tyrosine kinase inhibitors, endocrine/hormone therapy and checkpoint blockade using non-small cell lung cancer, breast and castration-resistant prostate cancer, and melanoma as classical examples, respectively. In addition, testing for resistance mechanisms and therapeutic approaches to overcoming resistance is addressed.
个性化癌症治疗的目标是根据驱动肿瘤生存和进展的基因组畸变来治疗肿瘤。大多数接受靶向治疗的患者通常会在一年内产生耐药性并出现疾病进展。本综述分别以非小细胞肺癌、乳腺癌、去势抵抗性前列腺癌和黑色素瘤为典型例子，重点探讨了对酪氨酸激酶抑制剂、内分泌/激素治疗和检查点阻断治疗产生耐药性的异质性机制。此外，还讨论了耐药机制检测以及克服耐药性的治疗方法。
